MRK1N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate and improving leverage gives Merck KGaA financial flexibility to fund research, capacity and strategic initiatives. Growing equity further supports balance-sheet resilience and reduces the risk that debt constrains operations over the next several quarters.
Healthy MarginsA healthy gross and operating margin profile indicates that Merck KGaA retains meaningful value from its healthcare products, life-science solutions and specialty materials. This provides a durable earnings base even while revenue growth remains uneven.
Positive Free Cash FlowPositive and improving trailing free cash flow supports continued investment, debt servicing and shareholder distributions. Although conversion is not optimal, the recovery from weaker prior periods shows the group can generate internal funding across its diversified businesses.
Bears Say
Uneven Revenue GrowthFlat revenue over several annual periods suggests that Merck KGaA has not yet established consistent top-line momentum. The TTM rebound is encouraging, but its durability remains uncertain across cyclical electronics demand and research-related markets.
Earnings And Return PressureDeclining net income and softer returns on equity indicate weaker profit efficiency than in earlier years. If sustained, this could limit internally funded growth and reduce the earnings benefit expected from Merck KGaA’s otherwise healthy margin structure.
Moderate Cash ConversionModerate and volatile cash conversion means reported profits do not consistently translate into deployable cash. This may reflect working-capital or investment demands and could constrain flexibility if weaker conversion persists alongside uneven earnings.
MRK1N FAQ
What was Merck KGaA’s price range in the past 12 months?
Currently, no data Available
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is $1.17T.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Nov 12, 2026 which is in 87 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on Aug 06, 2026. The company reported $42.73 earnings per share for the quarter, beating the consensus estimate of $40.079 by $2.651.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA does not currently pay dividends.
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 40.93.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of $42.73 in its last earnings report, beating expectations of $40.079. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in MX:MRK1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,826.92 (― Upside)
$2,826.92 (― Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.